<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039741</url>
  </required_header>
  <id_info>
    <org_study_id>P390</org_study_id>
    <secondary_id>PENPACT-1B</secondary_id>
    <secondary_id>10106</secondary_id>
    <secondary_id>PENTA 9/PACTG 390</secondary_id>
    <nct_id>NCT00039741</nct_id>
  </id_info>
  <brief_title>Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children</brief_title>
  <official_title>A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Little is known about what treatment combinations are best for HIV infected children. This
      study examined the long-term effectiveness of different anti-HIV drug combinations in
      children and strategies for switching treatment if the first treatment does not work. The
      study enrolled children who had not previously taken anti-HIV medication. Participants in
      this study were recruited in the United States, South America and Europe.

      Some European children may also enroll in a substudy that will observe changes in body fat in
      children taking anti-HIV medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral therapy in children aims to prolong clinical and immunologic health.
      Currently, there are no data defining a particular highly active antiretroviral therapy
      (HAART) strategy as the optimal first-line therapy for children. This study evaluated the
      long-term efficacy of two HAART regimens used as initial therapy: 1) two nucleoside reverse
      transcriptase inhibitors (NRTIs) plus a protease inhibitor (PI), and 2) two NRTIs plus a
      nonnucleoside reverse transcriptase inhibitor (NNRTI). It also evaluated different strategies
      for switching therapy when the initial regimen fails. The long-term nature of this study
      should clarify whether early switching of therapy improves immunologic and virologic
      outcomes, or results in a more rapid exhaustion of treatment options. The study was conducted
      in the United States and in Europe.

      Participants in this study had a CD4 cell count and viral load test during a screening visit.
      Participants had an entry visit that included blood and urine tests. Participants were then
      randomly assigned to one of four groups: Groups PI/1K and PI/30K received two NRTIs plus a
      PI; Groups NNRTI/1K and NNRTI/30K received two NRTIs plus an NNRTI. The medications allowed
      in the study were: abacavir, didanosine, emtricitabine, emtricitabine/tenofovir disoproxil
      fumarate, lamivudine, lamivudine/zidovudine, stavudine, tenofovir disoproxil fumarate,
      zalcitabine, and zidovudine (NRTIs); efavirenz and nevirapine (NNRTIs);
      efavirenz/emtricitabine/tenofovir disoproxil fumurate (NNRTI/NRTI); and
      amprenavir,atazanavir, darunavir, fosamprenavir calcium, indinavir, lopinavir/ritonavir,
      nelfinavir, saquinavir, ritonavir, and tipranavir (PIs). Note: Per the 06/28/05 amendment of
      this trial, emtricitabine, emtricitabine/tenofovir disoproxil fumarate, and tenofovir
      dioproxil fumarate were added to the list of medications that could be included in a
      participant's treatment regimen.

      For participants whose initial regimen failed, or who experienced clinical disease
      progression (indicated by the development of a new CDC Category C diagnosis) or other
      clinical disease progression at or after Week 24 of first-line therapy, second-line therapy
      was strongly encouraged. (However, if poor adherence was suspected as a possible reason for
      an increase in HIV viral load, the site and the clinician were to try to improve patient
      adherence and obtain additional confirmatory viral load values within a five-week time
      frame.) In second-line therapy, participants who initially took NRTIs with a PI switched to
      NRTIs and an NNRTI. Participants who initially took NRTIs and an NNRTI switched to NRTIs and
      a PI. The timing of the switch was based on the participant's group: Groups PI/1K and
      NNRTI/1K switched to second-line treatment when viral load was 1,000 copies/ml or greater;
      Groups PI/30K and NNRTI/30K switched to second-line treatment when viral load was 30,000
      copies/ml or greater. Participants who failed second-line therapy discontinued study
      treatment and were offered the best available therapy at the discretion of the clinician.

      Participants had study visits at Weeks 2, 4, 8, 12, 16, 24, and every 12 weeks thereafter
      until the drug regimen was switched to second-line treatment. Participants then had a
      re-entry visit and the schedule of visits restarted. Participants were in the study between 4
      and 7 years, depending on when they enrolled. All study visits included medical history, a
      physical exam, and blood collection. Urine collection occurred at most visits. Participants
      were asked to complete adherence questionnaires and PACTG participants underwent
      neuropsychological assessments at selected visits.

      All participants in this study were encouraged to coenroll in PACTG 219C, Long-Term Effects
      of HIV Exposure and Infection in Children. Participants in the European portion of the study
      may be asked to enroll in a substudy to observe the development and progression of
      lipodystrophy syndrome in children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml</measure>
    <time_frame>Baseline visit and 4 years after Study Entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Grade 3 or Higher Signs, Symptoms, or Laboratory Abnormalities Experienced</measure>
    <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
    <description>Adverse events were graded according to the following guidelines:
PACTG: &quot;The Manual for Expedited Reporting of Adverse Events to DAIDS&quot; (DAIDS EAE Manual) dated May 6, 2004.
PENTA: International Conference for Harmonization (ICH) requirements and the EU Clinical Trials Directive 2001/20/EC (20).
A rating of Grade 3 is severe and Grade 4 is life-threatening. The rate of serious (Grade 3 or above)events is reported as the number of events per 100 child/years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Significant HIV-related Clinical Events, Defined as CDC Category C (AIDS Defining) Diagnoses (Except for Recurrent Bacterial Infections)or Death</measure>
    <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Switching to an Alternative Class ART Regimen (Based on Initial Randomized Regimen)</measure>
    <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
    <description>25th Percentiles in weeks from randomization to starting an alternative class ART regimen (based on initial randomized regimen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HIV-1 RNA of 400 Copies/ml or Greater During First-line Therapy or Permanent Discontinuation of First-line Therapy</measure>
    <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
    <description>25th Percentiles in weeks from randomization HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HIV-1 RNA of 30,000 Copies/ml or Greater During Second-line Therapy or Permanent Discontinuation of Second-line Therapy</measure>
    <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
    <description>25th Percentiles in weeks from randomization to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children With an HIV-1 RNA Level Less Than 400 Copies/ml Regardless of Therapy at Week 204</measure>
    <time_frame>Week 204</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4% From Randomization to 4 Years</measure>
    <time_frame>Randomization to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children With HIV-1 RNA Less Than 400 Copies/ml and on Original Randomized Therapy at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>PI/1K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNRTI/1K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI/30K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNRTI/30K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)</intervention_name>
    <description>Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor</description>
    <arm_group_label>PI/1K</arm_group_label>
    <arm_group_label>PI/30K</arm_group_label>
    <arm_group_label>NNRTI/1K</arm_group_label>
    <arm_group_label>NNRTI/30K</arm_group_label>
    <other_name>2 NRTIs/PI, change@viral load 1000 copies/ml or higher</other_name>
    <other_name>2 NRTIs/PI, change@viral load 30,000 copies/ml or higher</other_name>
    <other_name>2 NRTIs/NNRTI, change@viral load 1000 copies/ml or higher</other_name>
    <other_name>2 NRTIs/NNRTI, change@viral load 30,000 copies/ml or higher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNRTIs (EFV, NVP)</intervention_name>
    <description>Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)
Prescribed per participant's doctor</description>
    <arm_group_label>NNRTI/1K</arm_group_label>
    <arm_group_label>NNRTI/30K</arm_group_label>
    <other_name>2 NRTIs/NNRTI, change@viral load 1000 copies/ml or higher</other_name>
    <other_name>2 NRTIs/NNRTI, change@viral load 30,000 copies/ml or higher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)</intervention_name>
    <description>Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)
Prescribed per participant's doctor</description>
    <arm_group_label>PI/1K</arm_group_label>
    <arm_group_label>PI/30K</arm_group_label>
    <other_name>2 NRTIs/PI, change@viral load 1000 copies/ml or higher</other_name>
    <other_name>2 NRTIs/PI, change@viral load 30,000 copies/ml or higher</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 30 days and younger than 18 years of age (may enroll up to the day before
             their 18th birthday)

          -  HIV infected

          -  Not previously on HAART or received anti-HIV drugs for less than 56 consecutive days
             after birth to prevent mother-to-infant HIV transmission. Participants who have
             previously received nevirapine for the prevention of mother-to-infant HIV transmission
             are not eligible for this study.

          -  Willing to use acceptable methods of contraception

        Exclusion Criteria:

          -  Grade 3 or 4 clinical or laboratory toxicity. More information on this criterion can
             be found in the protocol.

          -  Active opportunistic infection or a serious bacterial infection at the time of study
             entry

          -  Pancreas, nervous system, blood, liver, or kidney problems that make it impossible to
             take study medications

          -  Taking any medication that cannot be combined with the study medications in first-line
             therapy

          -  Received therapy for cancer

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross E. McKinney, Jr., MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann J. Melvin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases, Children's Hospital and Medical Center, Seattle, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hosp. Long Beach CA NICHD CRS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles NICHD CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. &amp; Research Ctr. Oakland, Ped. Clinical Research Ctr. &amp; Research Lab.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Med. Ctr.</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases &amp; Allergy</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF - Tampa NICHD CRS</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ. New Orleans NICHD CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WNE Maternal Pediatric Adolescent AIDS CRS</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - Robert Wood Johnson Med. School, Div. of Allergy, Immunology &amp; Infectious Diseases</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901-1969</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Ny Nichd Crs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia IMPAACT CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds.</name>
      <address>
        <city>Syracruse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology &amp; Infectious Diseases</name>
      <address>
        <city>Chapel HIll</city>
        <state>North Carolina</state>
        <zip>27599-7220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Univ. - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bahamas</country>
    <country>Brazil</country>
  </removed_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct/show/NCT00006304</url>
    <description>Click here for more information about ACTG 219C (NCT00006304)</description>
  </link>
  <reference>
    <citation>Brogly S, Williams P, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K; PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005 May 11;293(18):2213-20.</citation>
    <PMID>15886376</PMID>
  </reference>
  <reference>
    <citation>Havens PL. Principles of antiretroviral treatment of children and adolescents with human immunodeficiency virus infection. Semin Pediatr Infect Dis. 2003 Oct;14(4):269-85. Review.</citation>
    <PMID>14724792</PMID>
  </reference>
  <reference>
    <citation>Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis. 2003 Oct;14(4):286-94. Review.</citation>
    <PMID>14724793</PMID>
  </reference>
  <reference>
    <citation>McKinney RE Jr, Cunningham CK. Newer treatments for HIV in children. Curr Opin Pediatr. 2004 Feb;16(1):76-9. Review.</citation>
    <PMID>14758118</PMID>
  </reference>
  <results_reference>
    <citation>PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.</citation>
    <PMID>21288774</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2002</study_first_submitted>
  <study_first_submitted_qc>June 10, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2002</study_first_posted>
  <results_first_submitted>December 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2012</results_first_posted>
  <disposition_first_submitted>August 19, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 17, 2011</disposition_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at Pediatric AIDS Clinical Trials Group (PACTG) units in the U.S. and Puerto Rico, and Paediatric European Network for Treatment of AIDS (PENTA) units in Argentina, Austria, the Bahamas, Brazil, France, Germany, Italy, Romania, Spain, the United Kingdom and Ireland. Enrollment started 9/25/02 and ended 9/7/05.</recruitment_details>
      <pre_assignment_details>Participants were stratified by age (&lt;3 years versus 3+ years), origin (PACTG site or PENTA site), and exposure versus no exposure to antiretroviral therapy perinatally. 266 children were randomized, of whom 3 are excluded from all analyses (2 had consent withdrawn by parents after randomization, 1 was ineligible).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PI/1K</title>
          <description>Two nucleoside reverse transcriptase inhibitors (NRTI) plus a protease inhibitor (PI)with a regimen change recommended when viral load is 1000 copies/ml or higher</description>
        </group>
        <group group_id="P2">
          <title>NNRTI/1K</title>
          <description>2 NRTIs plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) with a regimen change recommended when viral load reaches 1,000 copies/ml or higher</description>
        </group>
        <group group_id="P3">
          <title>PI/30K</title>
          <description>Two NRTIs plus a PIwith a regimen change recommended when viral load is 30,000 copies/ml or higher</description>
        </group>
        <group group_id="P4">
          <title>NNRTI/30K</title>
          <description>2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Confounding medical condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed final visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PI/1K</title>
          <description>Two nucleoside reverse transcriptase inhibitors (NRTI) plus a protease inhibitor (PI)with a regimen change recommended when viral load is 1000 copies/ml or higher</description>
        </group>
        <group group_id="B2">
          <title>NNRTI/1K</title>
          <description>2 NRTIs plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) with a regimen change recommended when viral load reaches 1,000 copies/ml or higher</description>
        </group>
        <group group_id="B3">
          <title>PI/30K</title>
          <description>Two NRTIs plus a PIwith a regimen change recommended when viral load is 30,000 copies/ml or higher</description>
        </group>
        <group group_id="B4">
          <title>NNRTI/30K</title>
          <description>2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="263"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="5.7"/>
                    <measurement group_id="B2" value="7.0" spread="5.4"/>
                    <measurement group_id="B3" value="7.9" spread="5.4"/>
                    <measurement group_id="B4" value="6.9" spread="5.0"/>
                    <measurement group_id="B5" value="7.5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;30 days to &lt;=12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 months to &lt;=3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 to &lt;=9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;9 to &lt;=14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;14 years to &lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Sites in the US and Puerto Rico were enrolled through PACTG, and other sites were enrolled through PENTA</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bahamas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral Load</title>
          <description>Log10 HIV-1 RNA (copies/ml)</description>
          <units>Log10 copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="0.8"/>
                    <measurement group_id="B2" value="5.0" spread="0.8"/>
                    <measurement group_id="B3" value="5.0" spread="0.8"/>
                    <measurement group_id="B4" value="5.1" spread="0.8"/>
                    <measurement group_id="B5" value="5.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PENTA/PACTG site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PENTA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PACTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 percent (percentage of total lymphocytes that are CD4 cells)</title>
          <units>CD4%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="12"/>
                    <measurement group_id="B2" value="18" spread="10"/>
                    <measurement group_id="B3" value="18" spread="11"/>
                    <measurement group_id="B4" value="17" spread="12"/>
                    <measurement group_id="B5" value="18" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml</title>
        <time_frame>Baseline visit and 4 years after Study Entry</time_frame>
        <population>Intent-to-treat analyses for those subjects who had data at baseline and 4 years. Analyses were done by collapsing groups to examine drug class (regardless of switch point) and switch point (regardless of drug class).</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml</title>
          <population>Intent-to-treat analyses for those subjects who had data at baseline and 4 years. Analyses were done by collapsing groups to examine drug class (regardless of switch point) and switch point (regardless of drug class).</population>
          <units>log10 HIV-1 RNA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="0.09"/>
                    <measurement group_id="O2" value="-3.31" spread="0.09"/>
                    <measurement group_id="O3" value="-3.26" spread="0.09"/>
                    <measurement group_id="O4" value="-3.20" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Interval regression</method>
            <method_desc>Adjusted for baseline HIV-1 RNA, age (&lt;3 years vs 3 years), origin (PACTG vs PENTA sites), and perinatal ART exposure versus no exposure.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Interval regression</method>
            <method_desc>Adjusted for baseline HIV-1 RNA, age (&lt;3 years vs 3 years), origin (PACTG vs PENTA sites), and perinatal ART exposure versus no exposure.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Grade 3 or Higher Signs, Symptoms, or Laboratory Abnormalities Experienced</title>
        <description>Adverse events were graded according to the following guidelines:
PACTG: The Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual) dated May 6, 2004.
PENTA: International Conference for Harmonization (ICH) requirements and the EU Clinical Trials Directive 2001/20/EC (20).
A rating of Grade 3 is severe and Grade 4 is life-threatening. The rate of serious (Grade 3 or above)events is reported as the number of events per 100 child/years.</description>
        <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Grade 3 or Higher Signs, Symptoms, or Laboratory Abnormalities Experienced</title>
          <description>Adverse events were graded according to the following guidelines:
PACTG: The Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual) dated May 6, 2004.
PENTA: International Conference for Harmonization (ICH) requirements and the EU Clinical Trials Directive 2001/20/EC (20).
A rating of Grade 3 is severe and Grade 4 is life-threatening. The rate of serious (Grade 3 or above)events is reported as the number of events per 100 child/years.</description>
          <population>Intent to treat</population>
          <units>events/100 child-years</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.08" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.09" upper_limit="0.31"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.08" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.09" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Significant HIV-related Clinical Events, Defined as CDC Category C (AIDS Defining) Diagnoses (Except for Recurrent Bacterial Infections)or Death</title>
        <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Significant HIV-related Clinical Events, Defined as CDC Category C (AIDS Defining) Diagnoses (Except for Recurrent Bacterial Infections)or Death</title>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Switching to an Alternative Class ART Regimen (Based on Initial Randomized Regimen)</title>
        <description>25th Percentiles in weeks from randomization to starting an alternative class ART regimen (based on initial randomized regimen)</description>
        <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Switching to an Alternative Class ART Regimen (Based on Initial Randomized Regimen)</title>
          <description>25th Percentiles in weeks from randomization to starting an alternative class ART regimen (based on initial randomized regimen)</description>
          <population>Intent to treat</population>
          <units>Weeks (25th Percentile)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="295">Fewer than 50% of participants reached the switching criteria, so the median and 75th percentile are undefined.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="142">Fewer than 50% of participants reached the switching criteria, so the median and 75th percentile are undefined.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="142">Fewer than 50% of participants reached the switching criteria, so the median and 75th percentile are undefined.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="240">Fewer than 50% of participants reached the switching criteria, so the median and 75th percentile are undefined.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to HIV-1 RNA of 400 Copies/ml or Greater During First-line Therapy or Permanent Discontinuation of First-line Therapy</title>
        <description>25th Percentiles in weeks from randomization HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy.</description>
        <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to HIV-1 RNA of 400 Copies/ml or Greater During First-line Therapy or Permanent Discontinuation of First-line Therapy</title>
          <description>25th Percentiles in weeks from randomization HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy.</description>
          <population>Intent to treat</population>
          <units>Weeks (25th Percentile)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to HIV-1 RNA of 30,000 Copies/ml or Greater During Second-line Therapy or Permanent Discontinuation of Second-line Therapy</title>
        <description>25th Percentiles in weeks from randomization to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy</description>
        <time_frame>Up to 6 yrs. (average 4.85 yrs.)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to HIV-1 RNA of 30,000 Copies/ml or Greater During Second-line Therapy or Permanent Discontinuation of Second-line Therapy</title>
          <description>25th Percentiles in weeks from randomization to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy</description>
          <population>Intent to treat</population>
          <units>Weeks (25th Percentile)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="267"/>
                    <measurement group_id="O3" value="267"/>
                    <measurement group_id="O4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children With an HIV-1 RNA Level Less Than 400 Copies/ml Regardless of Therapy at Week 204</title>
        <time_frame>Week 204</time_frame>
        <population>Intent to treat. Numbers are reported among participants who had an HIV-1 RNA value and were in follow-up at week 204.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children With an HIV-1 RNA Level Less Than 400 Copies/ml Regardless of Therapy at Week 204</title>
          <population>Intent to treat. Numbers are reported among participants who had an HIV-1 RNA value and were in follow-up at week 204.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4% From Randomization to 4 Years</title>
        <time_frame>Randomization to 4 years</time_frame>
        <population>Intent to treat, for participants who had CD4% values available at 4 years and at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4% From Randomization to 4 Years</title>
          <population>Intent to treat, for participants who had CD4% values available at 4 years and at baseline.</population>
          <units>CD4 percent (% of total lymphocytes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="0.8"/>
                    <measurement group_id="O2" value="15.2" spread="0.8"/>
                    <measurement group_id="O3" value="15.1" spread="0.8"/>
                    <measurement group_id="O4" value="13.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children With HIV-1 RNA Less Than 400 Copies/ml and on Original Randomized Therapy at 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
        <population>Intent to treat - numbers are reported among participants who had an HIV-1 RNA value and were in follow-up at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Class/PI</title>
            <description>Participants randomized to receive a PI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O2">
            <title>Drug Class/NNRTI</title>
            <description>Participants randomized to receive an NNRTI-based regimen, regardless of switch point.</description>
          </group>
          <group group_id="O3">
            <title>Switch Point (1K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=1,000 copies/mL, regardless of drug class.</description>
          </group>
          <group group_id="O4">
            <title>Switch Point (30K)</title>
            <description>Participants randomized to switch to second-line therapy when HIV-1 RNA is &gt;=30,000 copies/mL, regardless of drug class.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children With HIV-1 RNA Less Than 400 Copies/ml and on Original Randomized Therapy at 24 Weeks</title>
          <population>Intent to treat - numbers are reported among participants who had an HIV-1 RNA value and were in follow-up at week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for up to 6.8 years, with a median of 5 years. The last study visit was August 31, 2009. ICH (International Conference for Harmonization) criteria were used for determining Serious Adverse Events.</time_frame>
      <desc>Only events with Grade 3 or greater are reported. No Other (Non-Serious) Adverse events occurred with 5% or greater frequency.</desc>
      <group_list>
        <group group_id="E1">
          <title>PI/1K</title>
          <description>Two nucleoside reverse transcriptase inhibitors (NRTI) plus a protease inhibitor (PI)with a regimen change recommended when viral load is 1000 copies/ml or higher</description>
        </group>
        <group group_id="E2">
          <title>NNRTI/1K</title>
          <description>2 NRTIs plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) with a regimen change recommended when viral load reaches 1,000 copies/ml or higher</description>
        </group>
        <group group_id="E3">
          <title>PI/30K</title>
          <description>Two NRTIs plus a PIwith a regimen change recommended when viral load is 30,000 copies/ml or higher</description>
        </group>
        <group group_id="E4">
          <title>NNRTI/30K</title>
          <description>2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Anemia megaloblastic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Aplastic anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Progressive external ophthalmoplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhea, viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis, perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Arthritis, viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Laryngitis, viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Esophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphkinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Croup, infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rash, maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ClinicalTrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>617-432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

